Avid is a clinical-stage product-focused molecular imaging company with significant expertise and IP in the field of molecular brain imaging. Avid has developed proprietary targeting agents to image amyloid plaques and is currently testing these compounds in clinical trials for the detection of Alzheimer's disease. Avid has demonstrated the proof of mechanism in human trials with these agents. The Avid team is also developing novel agents targeted to the vesicular monoamine transporter (VMAT-2) to image pathology in dementia with Lewy bodies (DLB), Parkinson's disease (PD), and has a research project in diabetes mellitus (DM). These agents have the potential to revolutionize early diagnosis and monitoring of disease.